ReviewJournal of natural medicines2026
Erinacerins from Hericium erinaceus: a review of their chemistry, bioactivities, and NMR characterization.
Review in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The medicinal mushroom Hericium erinaceus is a rich source of diverse bioactive secondary metabolites. Erinacerins are a significant class of structurally diverse secondary metabolites, comprising both nitrogen-containing alkaloids bearing an isoindolinone or pyridinone core and non-nitrogenous congeners. This review provides a comprehensive overview of 28 known erinacerins reported from H. erinaceus, detailing their isolation, structural elucidation, and diverse bioactivities. A key focus is directed toward their characterization by NMR spectroscopy, offering a systematic guide for the identification of this class of molecules. The discussion encompasses the reported inhibitory effects of erinacerins against enzymes such as acetylcholinesterase and α-glucosidase, as well as their anti-inflammatory and cytotoxic activities against various cancer cell lines, underscoring their pharmacological potential. This work highlights the significance of erinacerins as a valuable scaffold of bioactive metabolites for therapeutic applications.
Indexed as
Identifiers
42766259What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.